Contact
Privacy Policy
Term of Use
Purchase Terms
COVID-19 Statement

Company
- About
- Leadership
- Contact
Careers
- Job Openings
Investors & Media

Select Page

Development of a Novel Human Engineered Enzyme (ACN00177) for the Treatment of Homocystinuria

by aegleawebdev | Oct 27, 2020

Search

Recent Comments

Company

About
Leadership
Contact

Careers

Job Openings

Investors & Media

Company Overview
Press Releases
Events & Presentations
Stock Information
Financials
Corporate Governance
Resources

© 2023 Aeglea BioTherapeutics. Privacy Policy Terms of Use Purchase Terms

Welcome
About ARG1-D
Diagnosing ARG1-D
Managing ARG1-D
Patient Advocacy
Connect